DISORDERS OF PLASMA AND PLATELET PATHWAYS OF HEMOSTASIS IN PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH DISLIPOPROTEINEMIA

Parameters of lipid transport system as well as that of haemostasis have been studied in coronary heart disease (CHD) patients (n = 70) having at least one of two major CHD risk factors - arterial hypertension (AH) and dyslipoproteinemia (DLP). Patients with combination of AH and DLP significantly differed from those with isolated DLP by higher levels of total and low density lipoprotein cholesterol, triglycerides and apolipoprotein B. As compared with patients with isolated AH they differed by elevated systolic and diastolic blood pressure. The increased blood thrombogenicity (combination of disturbances in haemostasis resulted in enhanced thrombosis) was high both in hypertensive and dyslipidemic subjects. However, while in group with isolated DLP there was a predominance of decreased anticoagulation and fibrinolysis, in patients with isolated AH the major impact was related to elevated platelet aggregation. Thus, unfavorable shifts in lipoprotein and haemostasis parameters found in patients with AH and DLP could be regarded as markers of their atherothrombogenicity.

1. Габбасов З.А., Попов Е.Г., Гаврилов И.Ю. и др. Новый высокочувствительный метод анализа агрегации тромбоцитов. Лаб. дело 1989; 10: 15-18.

2. Кочетов А., Кобалава Ж., Дроздов В. и др. Комплексная оценка агрегатограмм и анализ функциональной активности тромбоцитов пациентов с артериальной гипертензией. Клин. лаб. диагн. 1999; 4: 43-45.

3. Энциклопедия клинических лабораторных тестов./Под ред. Н. Тица. М.: Лабинформ, 1997.

4. Breddin H.K., Lippold R., Bittner M., et al. Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG Study. Haemostatic parameters as risk factors in healthy volunteers. Atherosclerosis 1999; 144: 211-219.

5. Dichtl W., Stiko A., Eriksson P., et al. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 3025-3032.

6. Folsom A.R., Aleksic N., Park E., et al. Prospective study of fibri nolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 611-617.

7. Gupta S., Gupta V.K., Dhamija R.K., et al. Platelet aggregation patterns in normotensive and hypertensive subjects. Indian.J. Physiol. Pharmacol. 2002; 46: 379-382.

8. Hernandez R. Platelet aggregation in arterial hypertension. Invest. Clin. 1997; 38 (Suppl 2): 41-46.

9. Julius S. Coronary disease in hypertension: a new mosaic. J. Hypertens. Suppl. 1997; 15: S3-S10.

10. Junker R., Heinrich J., Schulte H., et al. Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Munster study. J. Hypertens. 1998; 16: 917-923.

11. Lee A.J. Haemorheological, platelet and endothelial factors in essential hypertension. J. Hum. Hypertens. 2002; 16: 557-562.

12. Lip G.Y., Li-Saw-Нее F.L. Does hypertension confer a hypercoagulable state? J. Hypertens. 1998; 16: 913-916.

13. Miller G.J. Lipoprotein and the haemostatic system in atherothrombotic disorders. Bull. Clin. Haemotol. 1994; 7: 713-732.

14. Mussoni L., Baldassarre D., Mannucci L., et al. Relationship between fibrinolytic and metabolic variables: a study in patients attending a lipid clinic. Ann. Med. 2000; 32: 134-141.

15. Puccetti L., Bruni F., Pasqui A.L., et al. Dyslipidemias and fibrinolysis. Ital. Heart. J. 2002; 3: 579-586.

16. Robbie L.A., Booth N.A., Brown A.J., et al. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 1996; 16: 539-545.

17. Wood D. Established and emerging cardiovascular risk factors. Am Heart J. 2001; 141 Suppl: S49-S57.